Delays in US FDA approvals for respiratory products
FLOVENT 44 approval is pending; any delay could impact Q4 US revenue growth.
GLENMARK / Q3-FY26 / risks
Keep the risk register visible.
Glenmark Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Currency depreciation impact on reported growth
Analyst questioned the quantum of currency benefit; management could not quantify, indicating potential overstatement of organic growth.
Gross margin pressure from product mix
Excluding out-licensing income, gross margin was lower at 65% due to product mix; recovery depends on new approvals.
Working capital normalization challenges
Despite progress, working capital days remain a focus; any slippage could impact cash flow targets.